Evaluation of the synthetic somatostatin analogue SMS 201-995 in patients with hypoglycaemia associated with hepatocellular carcinoma.
Joffe
B I
BI
Department of Medicine, University of the Witwatersrand Medical School, Parktown, Johannesburg, South Africa.
Kew
M C
MC
Panz
V R
VR
Kalk
W J
WJ
Shires
R
R
Wing
J
J
Seftel
H C
HC
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000150:complications*; D005934:Glucagon / Q000097:blood; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D007003:Hypoglycemia / Q000188:drug therapy* / Q000209:etiology; D007328:Insulin / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000097:blood; D008113:Liver Neoplasms / Q000097:blood / Q000150:complications*; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001786:Blood Glucose; D007328:Insulin; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D005934:Glucagon; D015282:Octreotide